Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial

Affiliations

¹ Breast Cancer Radiation Therapy Unit, Sheba Medical Center, Ramat Gan, Israel; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, Netherlands.
² Department of Radiation Oncology, Iridium Netwerk, Antwerp 2610, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium. Electronic address: philip.poortmans@telenet.be.

Comment

Orit Kaidar-Person et al. Lancet Oncol. 2021 Jul.

. 2021 Jul;22(7):e294.

doi: 10.1016/S1470-2045(21)00259-X.

¹ Breast Cancer Radiation Therapy Unit, Sheba Medical Center, Ramat Gan, Israel; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, Netherlands.
² Department of Radiation Oncology, Iridium Netwerk, Antwerp 2610, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium. Electronic address: philip.poortmans@telenet.be.

No abstract available

Conflict of interest statement

PP is a medical advisor of Sordina IORT Technologies. OK-P declares no competing interests.

Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial - Authors' reply.
Orecchia R, Maisonneuve P, Leonardi MC. Orecchia R, et al. Lancet Oncol. 2021 Jul;22(7):e298. doi: 10.1016/S1470-2045(21)00355-7. Lancet Oncol. 2021. PMID: 34197758 No abstract available.

Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial.
Orecchia R, Veronesi U, Maisonneuve P, Galimberti VE, Lazzari R, Veronesi P, Jereczek-Fossa BA, Cattani F, Sangalli C, Luini A, Caldarella P, Venturino M, Sances D, Zurrida S, Viale G, Leonardi MC, Intra M. Orecchia R, et al. Lancet Oncol. 2021 May;22(5):597-608. doi: 10.1016/S1470-2045(21)00080-2. Epub 2021 Apr 9. Lancet Oncol. 2021. PMID: 33845035 Clinical Trial.